Phio Scientific

Executive Summary

Phio Scientific is a Berlin-based diagnostics and proteomics company that has developed an integrated platform combining the ultra-compact Cellwatcher hardware with the cloud-based AI platform PHIOme. This system enables researchers to monitor cell growth, viability, motility, phenotype, and drug response in real-time without leaving their desks, offering a seamless and high-performance solution for live-cell analysis. Founded in 2012, the company targets the growing need for automated, non-invasive cell monitoring in drug discovery and academic research. By replacing traditional microscopy with a compact, AI-driven alternative, Phio aims to increase throughput and reduce manual effort in cell-based assays. The company's technology addresses key pain points in cell biology: data acquisition is automated via the Cellwatcher, and analysis is performed by PHIOme's AI models, providing actionable insights with minimal user intervention. While Phio has not disclosed funding or valuation, its presence in the competitive life sciences tools market suggests potential for growth. The platform's ability to integrate seamlessly into existing workflows positions it as a valuable tool for pharma and biotech companies. Near-term focus likely includes expanding commercial partnerships and advancing the platform's capabilities to capture a larger share of the live-cell analysis market.

Upcoming Catalysts (preview)

• Q4 2026Launch of next-generation Cellwatcher with enhanced sensitivity50% success
• Q2 2027Partnership with a top-20 pharmaceutical company for drug screening40% success